China
Africa
Explore chapters and articles related to this topic
Wavy Lines, Distorted Vision and Blur
Published in Amy-lee Shirodkar, Gwyn Samuel Williams, Bushra Thajudeen, Practical Emergency Ophthalmology Handbook, 2019
Central serous retinopathy: In a young or middle-aged man (but not exclusively), with a well circumscribed raised macula area without haemorrhage, central serous retinopathy is likely. Patients typically describe blurring, metamorphopsia, micropsia or a central relative scotoma, have an A-type personality, are stressed or have a history of steroid use.
The retina, optic nerve and vitreous humour
Published in Mary E. Shaw, Agnes Lee, Ophthalmic Nursing, 2018
Central serous retinopathy is a maculopathy affecting a younger age group than age-related macular degeneration. The cause is unknown and occurs in the 25- to 40-year age group, affecting men more than women. The sufferers tend to have an anxious disposition. The patients complain of a sudden painless loss of central vision, for example down to 6/18 with a central blur. The macula is elevated with a diagnostic light reflex around the macula.
How to master MCQs
Published in Chung Nen Chua, Li Wern Voon, Siddhartha Goel, Ophthalmology Fact Fixer, 2017
Central serous retinopathy gives rise to sensory retinal detachment due to an abnormality of the retinal pigment epithelium. The cause is unknown. It is more common in males than in females and is associated with a type A personality. Systemic and inhaled steroids have also been implicated. While a smoke stack is a classical picture in fluorescein angiography of this condition, it is seen in only 10% of cases. The rest give an ink blot appearance. Laser photocoagulation can speed up recovery but does not prevent recurrence. There is a small risk (2%) of inducing choroidal neovascularisation with laser.
A Case of Transient Visual Field Defect following Administration of Pfizer-BioNTech COVID-19 Vaccine
Published in Ocular Immunology and Inflammation, 2022
Almila Sarıgül Sezenöz, Sirel Gür Güngör, Seda Kibaroğlu
Ocular adverse effects following COVID-19 vaccination have been reported before. The first case of intraocular side effects of Pfizer®-BioNTech™ COVID-19 vaccine was reported by Fowler et al.3 The authors reported a case of acute onset central serous retinopathy 69 hours after being vaccinated.3 Several other cases of possible vaccine-related side effects including episcleritis, anterior scleritis, AMN, paracentral acute middle maculopathy, anterior uveitis bilateral arteritic anterior ischemic optic neuropathy, bilateral acute zonal occult outer retinopathy, panuveitis, acute retinal necrosis with reactivation of varicella zoster infection, parainfectious optic neuritis and herpes zoster reactivation have been reported.6,7,9,11–16 Most studies on vaccine-related side effects reveal symptom reduction during the analysis of the 10–20 days follow-up, implying that any new finding during this time frame, particularly in a healthy person, should be regarded as vaccine-related side effects unless proven otherwise.12 In our case, the symptoms started within 48 hours within this time frame described, so the rule is applicable. Also the Naranjo scale, which is a questionnaire for adverse drug reactions, was applied and the score was found to be 3, which indicate possible adverse drug reaction.
Overview of the clinical use of erdafitinib as a treatment option for the metastatic urothelial carcinoma: where do we stand
Published in Expert Review of Clinical Pharmacology, 2020
Alberto D’Angelo, Stefan Bagby, Ilaria Camilla Galli, Carlotta Bortoletti, Giandomenico Roviello
Ocular toxicity, including dry eye, xerophthalmia, keratitis, foreign body sensation, and corneal erosion was reported to be frequent during erdafitinib therapy and occurred in 28% of patients, with grade 3 AE in 6% of patients [35]. Central serous retinopathy or retinal pigment epithelial detachment was described in 25% of patients and were classified as grade 3 in 3% of patients. Most ocular adverse events were low grade and resolved with dose interruption or reduction. Ocular toxicity is another well-established side effect of erdafitinib and, consequently, patients should receive dry eye prophylaxis and monthly eye examinations for the first 4 months of therapy and every 3 months afterward [43], as advised by the FDA [35,40,41,44].
Non-macular chronic serous chorioretinopathy: a case series
Published in Clinical and Experimental Optometry, 2023
Danielle Kalberer, Shephali Patel
Identifying cases of non-macular serous retinopathy may be difficult due to subtlety or lack of classic visual symptoms. This case series demonstrates how non-macular chronic serous chorioretinopathy can occur ‘under-the-radar’ of both patients and providers. It serves as a reminder to optometrists that the condition does not always present as ‘classic’ central serous retinopathy (central location with the typical visual symptoms of blur and/or metamorphopsia).